Literature DB >> 11750735

Follicle-stimulating hormone and advanced follicle development in the human.

N S Macklon1, B C Fauser.   

Abstract

The great majority of human oocytes is destined to undergo atresia. Only follicles able to respond to stimulation by follicle-stimulating hormone (FSH) will enter the final stage of development and ovulate. While the role of FSH in early follicle development is unclear, late follicular development is FSH-dependent. FSH levels increase during the luteo-follicular transition and give rise to continued growth of a cohort of follicles. In the normo-ovulatory cycle, one follicle achieves a diameter of >8 mm and produces high concentrations of estradiol. In response to negative feedback from rising estradiol and inhibin levels, FSH levels fall in the late follicle phase. The dominant follicle has increased sensitivity to the falling FSH levels and continues growing. Follicles that initiate the latter stages of development after FSH levels begin to fall undergo atresia. The duration of this FSH window during which FSH levels are above the threshold required to stimulate ongoing development determines the number of follicles that can develop to the pre-ovulatory stage. Recognition of this concept has resulted in new approaches in ovulation induction treatment and ovarian hyperstimulation therapy for in vitro fertilization (IVF).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11750735     DOI: 10.1016/s0188-4409(01)00327-7

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  9 in total

1.  Possible influence of menstrual cycle on lymphocyte X chromosome mosaicism.

Authors:  K Gersak; M Perme-Pohar; A Veble; B M Gersak
Journal:  J Assist Reprod Genet       Date:  2014-11-16       Impact factor: 3.412

2.  Follicular competition in cows: the selection of dominant follicles as a synergistic effect.

Authors:  Alexander Lange; Robert Schwieger; Julia Plöntzke; Stefan Schäfer; Susanna Röblitz
Journal:  J Math Biol       Date:  2018-09-07       Impact factor: 2.259

3.  Micro-RNA378 (miR-378) regulates ovarian estradiol production by targeting aromatase.

Authors:  Shengyu Xu; Katja Linher-Melville; Burton B Yang; De Wu; Julang Li
Journal:  Endocrinology       Date:  2011-08-16       Impact factor: 4.736

Review 4.  Contemporary pharmacological manipulation in assisted reproduction.

Authors:  Judith A F Huirne; Cornelis B Lambalk; Andre C D van Loenen; Roel Schats; Peter G A Hompes; Bart C J M Fauser; Nick S Macklon
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Transactivation of micrornA-320 by microRNA-383 regulates granulosa cell functions by targeting E2F1 and SF-1 proteins.

Authors:  Mianmian Yin; Xiaorong Wang; Guidong Yao; Mingrong Lü; Meng Liang; Yingpu Sun; Fei Sun
Journal:  J Biol Chem       Date:  2014-05-14       Impact factor: 5.157

6.  Follicle stimulating hormone and its rate of change in defining menopause transition stages.

Authors:  MaryFran R Sowers; Huiyong Zheng; Daniel McConnell; Bin Nan; Sioban Harlow; John F Randolph
Journal:  J Clin Endocrinol Metab       Date:  2008-07-22       Impact factor: 5.958

7.  Analysis of androgen receptor and anti-Müllerian hormone pathways in human granulosa cells under luteinizing hormone treatment.

Authors:  Kuo-Chung Lan; Shiuh Young Chang; Fu-Jen Huang; Hsin-Jung Lin; Ching-Yuang Lin; Ko-En Huang; Hong-Yo Kang
Journal:  Reprod Biol Endocrinol       Date:  2013-02-21       Impact factor: 5.211

8.  Effect of anti-müllerian hormone on the development and selection of ovarian follicle in hens.

Authors:  S J Huang; L Purevsuren; F Jin; Y P Zhang; C Y Liang; M Q Zhu; F Wang; C L Jia; Z H Wei
Journal:  Poult Sci       Date:  2020-12-26       Impact factor: 3.352

9.  Reproductive Hormone and Transcriptomic Responses of Pituitary Tissue in Anestrus Gilts Induced by Nutrient Restriction.

Authors:  Shengyu Xu; Dingyue Wang; Dongsheng Zhou; Yan Lin; Lianqiang Che; Zhengfeng Fang; De Wu
Journal:  PLoS One       Date:  2015-11-18       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.